Unknown

Dataset Information

Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis.


ABSTRACT:

Background

Psoriasis is a chronic immune-mediated inflammatory skin disease affecting both adults and children. To better understand the efficacy-safety profile of biologics in children with moderate-to-severe psoriasis, this study aimed to analyze efficacy and safety data of randomized controlled trials (RCTs) performed in pediatric psoriasis and to compare efficacy outcomes in children with those in adults.

Methods

RCTs investigating biologics in children with moderate-to-severe psoriasis were identified in a systematic literature review. PASI75/90 treatment responses at weeks 11/12 were analyzed comparing biologics with control arms. Serious adverse events (SAEs) were analyzed at the end of each study. Efficacy data from RCTs in adults with psoriasis were selected for the

SUBMITTER: Golhen K 

PROVIDER: S-EPMC9548699 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature